[FDA phase II and phase III drug evaluation of antipsychotic agents].
Yagi
K
K
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents